B Capital earmarks $500 million for maiden healthcare fund
B Capital, a venture capital firm based in Los Angeles, has set aside $500 million to start a new fund that looks for business prospects in the healthcare industry. According to a statement, the B Capital Healthcare Fund I began when Dr. Robert Mittendorff joined B Capital as a General Partner in April 2021 to oversee the fund and its larger global healthcare activities.
The healthcare team of the fund is concentrated on allocating money to category-defining businesses that are developing ground-breaking products and solutions that will shape the future of healthcare, it was said. According to Howard Morgan, chair and general partner of B Capital, "B Capital has decades of combined operating expertise in the healthcare industry and a deep technical emphasis that allows us to select and assist the top companies in the space.
Morgan said B Capital’s approach to global venture and growth investment, including its partnership with Boston Consulting Group (BCG), places founders and management teams front-and-centre and surrounds them with resources they need to transform large markets. B Capital in India is currently invested in companies such as B2B vendor digitisation platform for brands and enterprises Bizongo, online trucking platform BlackBuck, social commerce startup Meesho, edtech major Byju’s, and online pharmacy startup Pharmeasy.
“Technological advancements in biology, AI, and automation are transforming the industry, with business models seeing the convergence of traditional players in novel ways. This moment presents a unique opportunity for B Capital to leverage our dedicated healthcare capital and active investment strategy to find and support companies advancing the healthcare sector,” Mittendorff said.
The current B Capital global healthcare portfolio includes over 20 companies in the United States, Asia and Europe, spanning early venture to late growth venture, across health-tech, digital health, biotech and med-tech. The latest additions include Hotspot Therapeutics, an AI-enabled drug discovery company; Triumvira, a novel cell therapy platform in clinical development; CapitalRX, a tech platform for pharmacy benefits management, and Carlsmed, an AI-enabled personalized spinal implant company.
B Capital announced the closing of Growth Fund III and linked funds in January of this year, with total capital commitments of almost $2.1 billion. B Capital now has about $6.3 billion in assets under management after these fund closes. According to Raj Ganguly, co-founder and managing partner of B Capital, the company's greater corpus is anticipated to assist it continue to be optimistic about the India and Southeast Asia opportunities as it seeks to write typical checks in the $50 million range. The $250 million life sciences and healthcare fund formed by Eight Roads Ventures last year and HealthQuad are two more funds with a focus on healthcare and interests in India.
The healthcare team of the fund is concentrated on allocating money to category-defining businesses that are developing ground-breaking products and solutions that will shape the future of healthcare, it was said. According to Howard Morgan, chair and general partner of B Capital, "B Capital has decades of combined operating expertise in the healthcare industry and a deep technical emphasis that allows us to select and assist the top companies in the space.
Morgan said B Capital’s approach to global venture and growth investment, including its partnership with Boston Consulting Group (BCG), places founders and management teams front-and-centre and surrounds them with resources they need to transform large markets. B Capital in India is currently invested in companies such as B2B vendor digitisation platform for brands and enterprises Bizongo, online trucking platform BlackBuck, social commerce startup Meesho, edtech major Byju’s, and online pharmacy startup Pharmeasy.
“Technological advancements in biology, AI, and automation are transforming the industry, with business models seeing the convergence of traditional players in novel ways. This moment presents a unique opportunity for B Capital to leverage our dedicated healthcare capital and active investment strategy to find and support companies advancing the healthcare sector,” Mittendorff said.
The current B Capital global healthcare portfolio includes over 20 companies in the United States, Asia and Europe, spanning early venture to late growth venture, across health-tech, digital health, biotech and med-tech. The latest additions include Hotspot Therapeutics, an AI-enabled drug discovery company; Triumvira, a novel cell therapy platform in clinical development; CapitalRX, a tech platform for pharmacy benefits management, and Carlsmed, an AI-enabled personalized spinal implant company.
B Capital announced the closing of Growth Fund III and linked funds in January of this year, with total capital commitments of almost $2.1 billion. B Capital now has about $6.3 billion in assets under management after these fund closes. According to Raj Ganguly, co-founder and managing partner of B Capital, the company's greater corpus is anticipated to assist it continue to be optimistic about the India and Southeast Asia opportunities as it seeks to write typical checks in the $50 million range. The $250 million life sciences and healthcare fund formed by Eight Roads Ventures last year and HealthQuad are two more funds with a focus on healthcare and interests in India.
